Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients

Graphical abstract

Highlights

- The long-term immunogenicity of anti-COVID-19 mRNA vaccines in LT recipients remains unknown.
- COVID-19-naïve LT recipients maintained antibody responses 6 months after Pfizer-BioNTech® BNT162b2 vaccination in 78.8% of cases.
- All COVID-19-recovered LT recipients were antibody responders 6 months after the Pfizer-BioNTech® BNT162b2 vaccine.
- The daily dose of mycophenolate mofetil was the main determinant of vaccination failure in COVID-19-naive patients.

Authors

Pierluigi Toniutto, Edmondo Falleti, Sara Cmet, ..., Francesco Curcio, Laura Regattin, Lucrezia Grillone

Correspondence
pierluigi.toniutto@uniud.it (P. Toniutto).

Lay summary

The immunogenicity of anti-SARS-CoV-2 vaccination in liver transplant recipients is currently unknown. Herein, we show that liver transplant recipients who have not previously had COVID-19 are less likely to mount effective antibody responses to vaccination than a control population. The main determinant of vaccination failure was the use of the immunosuppressive drug mycophenolate mofetil.
Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients

Pierluigi Toniutto1,*, Edmondo Falleti2, Sara Cmet2, Annarosa Cussigh2, Laura Veneto1, Davide Bitetto1, Ezio Fornasiere1, Elisa Fumolo1, Carlo Fabris1, Assunta Sartor3, Roberto Peressutt4, Francesco Curcio2, Laura Regattin5, Lucrezia Grillone6

1Hepatology and Liver Transplantation Unit, Department of Specialized Medicine, Udine University Hospital, Udine, Italy; 2Clinical Pathology, Udine University Hospital, Udine, Italy; 3Microbiology Unit, Department of Laboratory Medicine, Udine University Hospital, Udine, Italy; 4Regional Center of Liver Transplantation, Udine University Hospital, Udine, Italy; 5Hospital Health Management, Udine University Hospital, Udine, Italy; 6Department of Medical Area (DAME), Udine University Hospital, Udine, Italy

Background & Aims: The long-term immunogenicity of anti-SARS-CoV-2 vaccines in liver transplant (LT) recipients is unknown. We aimed to assess the long-term antibody response of the Pfizer-BioNTech® BNT162b2 vaccine in LT recipients compared to controls.

Methods: LT recipients underwent anti-SARS-CoV-2 anti-receptor-binding domain protein IgG (anti-RBD) and anti-nucleocapsid protein IgG antibody (anti-N) measurements at the first and 1, 4 and 6 months after the second vaccination dose.

Results: One hundred forty-three LT recipients and 58 controls were enrolled. At baseline, 131/143 (91.6%) LT recipients tested anti-N negative (COVID-19 naïve), and 12/143 (8.4%) tested were enrolled. At baseline, 131/143 (91.6%) LT recipients tested anti-N negative (COVID-19 naïve), and 12/143 (8.4%) tested positive (COVID-19 recovered) compared to negative controls. Among COVID-19 naïve, 22.1% were anti-RBD positives 1 month after the first vaccine dose, while 66.4%, 77%, and 78.8% were 1, 4 and 6 months following the second vaccine dose. In contrast, 100% of controls were positive at 4 months (p < 0.001). The median anti-RBD titer 4 months after the second vaccine dose was significantly lower (32 U/ml) in COVID-19 naïve than in controls (852 U/ml, p < 0.0001). A higher daily dose of mycophenolate mofetil (MMF) (p < 0.001), higher frequency of ascites (p = 0.012), and lower serum leukocyte count (p = 0.016) were independent predictors of anti-RBD negativity at 6 months. All COVID-19 recovered patients tested positive for anti-RBD at each time point. The median antibody titer was similar in those taking MMF (9,400 U/ml, 11,925 U/ml, 13,305 U/ml, and 10,095 U/ml) or not taking MMF (13,950 U/ml, 9,575 U/ml, 3,500 U/ml, 2,835 U/ml, p = NS) 3 weeks after the first and 1, 4 and 6 months after the second vaccine dose, respectively.

Conclusions: In COVID-19-naïve LT recipients, the immunogenicity of anti-SARS-CoV-2 vaccination was significantly lower than that in controls. MMF was the main determinant of vaccination failure in SARS-CoV-2 naïve patients.

Keywords: mRNA vaccine; mycophenolate mofetil; liver transplantation.

Received 22 August 2021; received in revised form 3 February 2022; accepted 10 February 2022; available online 10 March 2022

*Corresponding author. Address: Hepatology and Liver Transplantation Unit, Department of Specialized Medicine, Udine University Hospital, Udine, Italy; Tel.: +39 0432 552636, fax: +39 0432 559487.
E-mail address: pierluigi.toniutto@uniud.it (P. Toniutto).
https://doi.org/10.1016/j.jhep.2022.02.015

Lay summary: The immunogenicity of anti-SARS-CoV-2 vaccination in liver transplant recipients is currently unknown. Herein, we show that liver transplant recipients who have not previously had COVID-19 are less likely to mount effective antibody responses to vaccination than a control population. The main determinant of vaccination failure was the use of the immunosuppressive drug mycophenolate mofetil.

© 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

The new coronavirus pathogen, SARS-CoV-2, has been identified as the cause of COVID-19.1 Preliminary reports indicated that in liver transplant (LT) recipients, the clinical outcome following COVID-19 was better compared to other solid organ transplant recipients2 and not per se worse compared to the general population.3 However, more recent reports indicate that mortality in LT recipients remains particularly elevated.4,5 Two anti-SARS-CoV-2 vaccines based on mRNA technology (Pfizer-BioNTech® BNT162b2 and Moderna® mRNA-1273)6,7 have been approved. After the administration of 2 doses of these vaccines in immunocompetent patients, nearly all of them developed neutralizing antibodies against SARS-CoV-2 s-receptor-binding domain (RBD) protein.8 The development of neutralizing antibodies seems to reduce the risk of symptomatic severe SARS-CoV-2-related disease in immunocompetent patients.9 However, in LT recipients, the short-term (up to 3 months) humoral immune response induced by SARS-CoV-2 mRNA vaccines seems to be lower than that in immunocompetent patients.10–12 At present, no data are available regarding the rate and duration of the immune response after vaccination in the long term (up to 6 months) in this population. Despite this, all scientific societies recommend that LT patients should undergo 2 anti-SARS-CoV-2 doses with mRNA vaccines 3–6 months after LT, when immunosuppression can be reduced,13–15 with the possibility of a third booster dose.16 The aim of this prospective study was to assess the safety and the long-term (up to 6 months) humoral immune response induced by 2 doses of the Pfizer-BioNTech® BNT162b2 vaccine in a cohort of LT recipients compared to healthy controls.
Materials and methods

Study protocol

The staff at the academic hospital in our Italian region launched the anti-SARS-CoV-2 vaccination program for all LT recipients, adopting 2 doses of the Pfizer-BioNTech® BNT162b2 vaccine, in March 2021. Both vaccine doses were administered directly in the hospital for all LT recipients who were in long-term follow-up at the hospital hepatology and liver transplantation unit. Patients fulfilling this condition along with their demographic and clinical characteristics were extracted from the electronic database. The exclusion criteria were aged <18 years at transplant, pregnancy, past known SARS-CoV-2 infection, and LT performed less than 3 months before vaccination. A group of physicians and nurses without known past SARS-CoV-2 infection who followed patients in the clinic served as controls. All patients and controls provided written informed consent to the vaccination protocol and to participate in this study, which was approved by the regional Ethics Committee and conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution’s human research committee.

Before vaccination, both patients and controls completed a detailed interview reporting the presence of signs and/or symptoms (i.e., fever, cough, anosmia, and diarrhea), suggesting recent or past SARS-CoV-2 exposure. In addition, controls were periodically tested for SARS-CoV-2 infection via real-time reverse transcription PCR (RT-PCR) on nasopharyngeal swabs. A vaccination self-reported side effects questionnaire was administered to participants within 30 days of receipt of the second vaccination dose.

In all patients, a blood sample was collected at the following time points: at the first and the second vaccine doses (performed 19 days after the first) and at 1 (31±2 days), 4 (125±5 days), and 6 months (165±4 days) thereafter. One blood sample was collected 4 months (134±15 days) after the second vaccine dose in controls (Fig. 1). Anti-SARS-CoV-2-N protein IgM and IgG antibodies (Shenzhen Yhlo Biotech Co. Ltd) and anti-spike glycoprotein-specific immunoglobulin G receptor-binding domain (s-RBD) antibodies (Roche Elecsys®, F. Hoffmann-La Roche Ltd) were measured in blood samples collected at every time point in both LT patients and controls. In accordance with the manufacturer’s inserts, cut-off values used to identify positive patients were >10.0 kAU/L and ≥0.8 U/ml for the anti-SARS-CoV-2 N and s-RBD protein antibodies, respectively.

Statistical analysis

Statistical analysis was performed by means of Stata 15.1 statistical software (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). Since normality testing of continuous variables failed in approximately half of the cases, a non-parametric rank-sum (Mann-Whitney) test was used, and data are presented as medians and IQRs. The comparison of categorical variables was carried out using the Pearson chi-square test, and data are presented as frequencies (%). Stepwise logistic regression analysis with a forward approach was used to select independent predictors for the development of a positive anti-SARS-CoV-2 vaccine-induced humoral response. All variables showing a p value ≤0.10 in the univariate analysis were included. Pseudo R², the area under the ROC curve, and the percentage of correct classification are presented as quality estimations of the regression model. Multivariate linear regression analysis with a stepwise forward approach was used to discriminate the best fitting variables in predicting the antibody response after vaccination, considering antibody titer as a continuous variable. All variables significantly associated with antibody response post-vaccination in the univariate regression test were selected to run in the multivariate linear model.

Results

Patients

One hundred and sixty-four LT recipients were selected for enrollment in the study. Among them, 19 (11.6%) declined to participate in the vaccination program, and 2 did not receive the second vaccine dose: 1 died due to the progression of hepatocellular carcinoma recurrence, and the other was lost to follow-up. Thus, 143 LT recipients and 58 healthy controls were ultimately evaluated. LT recipients were more frequently male (71.7% vs. 32.9%, p<0.001) and older (67.7 vs. 47.6 years, p<0.001) than controls.

![Fig. 1. Timing schedule of the administration of the Pfizer-BioNTech® BNT162b2 vaccine doses and of the measurements of serum anti-SARS-CoV-2 antibodies in blood samples collected in liver-transplanted patients and controls.](image-url)
Prevalence of prevaccination anti-SARS-CoV-2-N protein antibodies in LT recipients and controls

None of the LT recipients or controls reported in the interview as having a current or recovered SARS-CoV-2 infection. A positive anti-SARS-CoV-2-N antibody test, suggesting a history of asymptomatic previous SARS-CoV-2 infection, was detected only in the sample collected before vaccination in 12/143 (8.4%) LT recipients and in none of the controls. Table 1 reports the main demographic and clinical characteristics of patients with regard to the results of the anti-SARS-CoV-2-N protein antibody test. Antibody-positive patients presented a higher BMI (28.8 vs. 26.0 kg/m², p = 0.010), were less frequently transplanted for alcohol-related liver disease (33% vs. 44.3%) and more frequently for hepatitis B (25% vs. 16%) (p = 0.036), and had a higher prevalence of diabetes mellitus (66.7% vs. 35.1%, p = 0.031) or recurrent post-transplant cirrhosis with esophageal varices (25% vs. 4.6%, p = 0.005) than antibody-negative patients. No significant differences between the 2 groups regarding either the immunosuppressive treatment schedule or the serum levels of immunosuppressive drugs were recorded. Considering this unexpected finding, these 2 groups of LT recipients were analyzed separately and classified as COVID-19-naïve (n = 131) and COVID-19-recovered (n = 12).

Anti-SARS-CoV-2 s-RBD antibody response after BNT162b2 vaccination in COVID-19 naïve patients and controls

The median (IQR) time from LT to vaccination was 94 (49–189) months. At 4 and 6 months after the second vaccine dose, data were available in 126/131 (96.2%) and 123/131 (93.9%) LT recipients, respectively, since 5 and 3 patients were lost to follow-up at each time point. The number of LT recipients who tested positive for prevaccination anti-SARS-CoV-2-N protein IgG/IgM antibodies was 10/131 (8.4%) in COVID-19-naïve patients and none in COVID-19-recovered patients. No significant differences between the 2 groups regarding either the immunosuppressive treatment schedule or the serum levels of immunosuppressive drugs were recorded.

Table 1. Baseline demographic and clinical characteristics of the studied population.

|                      | COVID-19-naïve (n = 131) | COVID-19-recovered (n = 12) | p value |
|----------------------|-------------------------|-----------------------------|---------|
| Age at LT (years)    | 57.9 (51.8-62.8)        | 57.5 (52.5-59.8)            | 0.453   |
| Male sex             | 92 (70.2)               | 10 (83.3)                   | 0.337   |
| BMI (kg/m²)          | 26.0 (23.5-28.7)        | 28.8 (27.2-30.8)            | 0.010   |
| Months between LT and vaccination | 94 (19-489)     | 157 (87-203)                | 0.192   |
| Etiology: HCV, HBV, NASH, AH, Al other (%) | 28, 21, 0, 58, 13, 11 (21.4, 16.0, 0.0, 44.3, 9.9, 8.4) | 2, 3, 1, 4, 1, 1 (16.7, 25.0, 8.3, 33.3, 8.3, 8.3) | 0.036   |
| HCC                  | 47 (35.9)               | 2 (16.7)                    | 0.180   |
| DM                   | 46 (35.1)               | 8 (66.7)                    | 0.031   |
| Dyslipidemia         | 29 (22.1)               | 4 (33.3)                    | 0.178   |
| Alcohol consumption >40 g/day | 9 (6.9)               | 1 (8.3)                     | 0.849   |
| HTN                  | 58 (44.3)               | 6 (50.0)                    | 0.703   |
| Presence of esophageal varices | 6 (4.6)               | 3 (25.0)                    | 0.005   |
| Presence of ascites  | 4 (3.1)                 | 1 (8.3)                     | 0.341   |
| IS treatment         |                         |                             |         |
| Tacrolimus           | 85 (64.9)               | 8 (66.7)                    | 0.901   |
| Cyclosporine         | 31 (23.3)               | 4 (33.3)                    | 0.456   |
| MMF                  | 58 (44.3)               | 6 (50.0)                    | 0.703   |
| Everolimus           | 12 (9.2)                | 0 (0.0)                     | 0.273   |
| Prednisone           | 13 (9.9)                | 1 (8.3)                     | 0.859   |
| Double-triple IS including MMF | 51 (38.9)               | 6 (19.5)                    | 0.454   |
| MMF+T+E+P;+T+P;+C+P (%) | 30, 16, 2, 1, 0, 2 (22.9, 12.2, 1.5, 0.8, 0.0, 0.0, 0) | 4, 1, 0, 0, 1, 0 (33.3, 8.3, 0.0, 0.0, 8.3, 0) | 0.036   |
| Double-triple IS excluding MMF | 14 (10.7)               | 0 (0.0)                     | 0.233   |
| T+E, T+A, T+P, C+P, T+E+P (%) | 3, 1, 7, 1, 2 (23.3, 0.8, 5.3, 0.8, 1.5) | 0, 0, 0, 0, 0 |         |
| Any double IS therapy | 61 (46.6)               | 4 (31.7)                    | 0.745   |
| Any triple IS therapy | 4 (3.1)                 | 1 (8.3)                     | 0.341   |
| IS levels with respect to reference* |                         |                             |         |
| Below                | 63 (48.1)               | 7 (58.3)                    | 0.497   |
| Above                | 6 (4.6)                 | 0 (0.0)                     | 0.449   |
| Serum IS drug levels or daily dose* |                         |                             |         |
| Tacrolimus (ng/ml)   | 3.05 ±0.82              | 4.12 ±0.62                  | 0.581   |
| Cyclosporine (ng/ml) | 172 ±8.0                | 11.8 ±2.2                   | 0.440   |
| MMF (g/day)          | 0.73 ±0.08              | 0.88 ±0.27                  | 0.602   |
| Everolimus (ng/ml)   | 0.0 ±0.0                | 0.43 ±0.14                  | 0.321   |
| Prednisone (mg/day)  | 0.42 ±0.42              | 0.860                       |         |
| Hemoglobin (g/dl)    | 13.5 (12.1-14.8)        | 12.5 (12.0-14.6)            | 0.378   |
| Leukocytes (n/µl)    | 5,640 (4,500-6,590)     | 6,420 (4,825-7,610)         | 0.214   |
| Neutrophils (n/µl)   | 3,357 (2,725-4,175)     | 3,687 (2,736-4,424)         | 0.749   |
| Albumin (g/dl)       | 4.23 (4.07-4.53)        | 4.08 (3.75-4.29)            | 0.067   |
| Total bilirubin (mg/dl) | 0.60 (0.42-0.90)       | 0.67 (0.54-0.86)            | 0.340   |
| eGFR (ml/min/1.73 m²) | 59.1 (45.9-75.6)     | 55.2 (45.5-68.8)            | 0.600   |
| AST (IU/ml)          | 18 (15-24)              | 24 (18-27)                  | 0.002   |
| ALT (IU/ml)          | 16 (11-23)              | 19 (15-28)                  | 0.206   |
| INR                  | 1.04 (0.98-1.13)        | 1.02 (0.96-1.11)            | 0.664   |
| 25-OH-Vitamin D (ng/ml) | 31 (26-35.0)         | 33.3 (27.8-41.6)            | 0.224   |

Patients were divided with regard to the presence (COVID-19-recovered) or absence (COVID-19-naïve) of prevaccination anti-SARS-CoV-2-N protein IgG/IgM antibodies. Categorical variables are presented as frequencies (%), and the Pearson chi-square test was used for statistical comparisons. Continuous variables are presented as medians (IQR), and immunosuppressive drug serum levels are presented as the means ±SE. The rank-sum test (Mann-Whitney) was used for statistical comparisons.

A, azathioprine; AH, alcoholic hepatitis; AI, autoimmune hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, cyclosporine; DM, diabetes mellitus; E, everolimus; eGFR, estimated glomerular filtration rate; HCC, hepatocellular carcinoma; HTN, arterial hypertension; INR, international normalized ratio; IS, immunosuppressive; LT, liver transplantation; NASH, non-alcoholic steatohepatitis; MMF, mycophenolate mofetil; P, prednisone; T, tacrolimus.

*Reference blood levels evaluated within 1 month before vaccination for each IS drug were calculated in accordance with Cillo et al.

154 Journal of Hepatology 2022 vol. 77 | 152–162
positive for anti-s-RBD after each vaccination time point was as follows: 29/102 (22.1%) 3 weeks (19 days) after the first vaccine dose, 87/44 (66.4%) after 1 month (31±2 days), 97/29 (77%) after 4 months (125±5 days), and 97/26 (78.8%) after 6 months (165±4 days) compared to 58/58 (100%) of controls evaluated 4 months (134±15 days) following the second vaccine dose. Ten patients developed a late (between the first and fourth months) positive antibody response after vaccination, and none of the tested positive patients became antibody-negative within 6 months post-vaccination. The median anti-s-RBD antibody titers at 4 (32 U/ml) and 6 (28.5 U/ml) months remained stable in LT recipients, but were significantly lower (32 U/ml) than those in the controls (852 U/ml, p <0.0001) at 4 months (Fig. 2).

Factors influencing the anti-SARS-CoV-2 s-RBD IgG response after BNT162b2 vaccination in COVID-naïve patients

In the multivariate analysis, independent predictors of immune response failure (anti-SARS-CoV-2 s-RBD IgG antibody titer <0.8 U/ml) 3 weeks after the first dose of vaccination were alcohol consumption >40 g/day (p <0.001), taking a higher daily dose of mycophenolate mofetil (MMF) (p = 0.002), and having a lower estimated glomerular filtration rate (eGFR) (p = 0.016) (Table 2). In addition to taking a higher daily dose of MMF, immunosuppression employing >2 drugs, having lower serum leucocytes and being older at LT were selected as independent predictors of unsuccessful antibody response 1 and 4 months after the second vaccine dose, respectively (Table S1 and S2). A higher daily MMF dose assumption (p <0.001), a more frequent presence of ascites (p = 0.012) and having a lower number of leukocytes (p = 0.016) were selected as independent predictors of the negative antibody response 6 months after vaccination (Table 3). Moreover, patients treated with immunosuppressive schedules, including MMF, compared to those excluding MMF, presented significantly lower median antibody titers at each time point after vaccination (Fig. 3). The contribution of each immunosuppressive drug as well as any combination of immunosuppressive drugs in influencing the anti-SARS-CoV-2 s-RBD antibody titer, evaluated at each time point after vaccination, is presented in Table S3. In the stepwise multiple linear analysis, the daily dose of MMF and age at LT were selected as independent regressors of the entire span of anti-SARS-CoV-2 s-RBD antibody titers at every time point after vaccination. An eGFR and alcohol consumption >40 g/day were selected factors associated with the anti-SARS-CoV-2 s-RBD antibody titer at 3 weeks after the first vaccine dose and at 1 month after the second vaccine dose (Table S4).

To identify patients who developed a strong antibody response after the full course of vaccination, the anti-SARS-CoV-2 s-RBD IgG antibody cut-off titer was selected at 100 U/ml. This was derived from the observation that adoptive transfer of purified polyclonal IgG from convalescent macaques robustly protected naïve recipient rhesus macaques against challenge with SARS-CoV-2 when the antibody titer was at least 100 U/ml.17 Considering this cut-off level, the number of patients who tested positive for anti-SARS-CoV-2 s-RBD IgG antibodies at 1, 4 and 6 months after the second vaccine dose was 51 (38.9%), 45 (35.7%) and 36 (29.3%), respectively. In the multivariate analysis, independent predictors of the achievement of a strong antibody response (>100 U/ml) were a younger age at LT (p = 0.0013), alcohol consumption <40 g/day (p <0.001) and taking a lower daily dose of MMF (p <0.001) at 1 month and no alcohol...
Table 2. Association of prevaccination demographic and clinical characteristics with antibody responses 3 weeks after the first dose of the Pfizer BTN162b2 vaccine.

|                              | Anti-s-RBD IgG negative (n = 102) | Anti-s-RBD IgG positive (n = 29) | p value | OR     | 95% CI | p value |
|------------------------------|----------------------------------|----------------------------------|---------|--------|--------|---------|
| **Age at LT (years)**        | 59.5 (54.1-63.4)                 | 54.6 (48.3-59.1)                 | 0.008   |        |        |         |
| **Male sex**                 | 74 (72.6)                        | 18 (62.1)                        | 0.276   |        |        |         |
| **BMI (kg/m²)**              | 25.5 (23.4-28.7)                 | 26.4 (23.8-29.3)                 | 0.407   |        |        |         |
| **Months between LT and vaccination** | 84.8 (36.7-189)                   | 153.9 (72.4-194.6)               | 0.040   |        |        |         |
| **HCV, HBV, AH, AI, other (%)** | 21, 18, 49, 7, 7 (20.6, 17.6, 48.0, 6.9, 6.9) | 7, 3, 9, 6, 4 (24.1, 10.3, 31.0, 20.7, 13.8) | 0.092   |        |        |         |
| **HCC**                      | 38 (37.3)                        | 9 (31.0)                         | 0.538   |        |        |         |
| **DM**                       | 37 (36.3)                        | 9 (31.0)                         | 0.602   |        |        |         |
| **Dyslipidemia**             | 23 (22.6)                        | 6 (20.7)                         | 0.831   |        |        |         |
| **Alcohol consumption >40 g/day** | 9 (8.8)                          | 0 (0.0)                          | <0.001  | <0.001 | <0.001 |         |
| **HTN**                      | 44 (43.1)                        | 14 (48.3)                        | 0.623   |        |        |         |
| **Presence of esophageal varices** | 5 (4.9)                          | 1 (3.5)                          | 0.741   |        |        |         |
| **Presence of ascites**      | 3 (2.9)                          | 1 (3.5)                          | 0.889   |        |        |         |
| **IS treatment**             |                                  |                                  |         |        |        |         |
| **Tacrolimus**               | 63 (61.8)                        | 22 (75.9)                        | 0.160   |        |        |         |
| **Cyclosporine**             | 26 (25.5)                        | 5 (17.2)                         | 0.356   |        |        |         |
| **MMF**                      | 57 (55.9)                        | 1 (31.7)                         | <0.001  |        |        |         |
| **Everolimus**               | 10 (9.8)                         | 2 (4.9)                          | 0.632   |        |        |         |
| **Prednisone**               | 11 (10.8)                        | 2 (6.9)                          | 0.537   |        |        |         |
| **Double-triple IS including MMF** | 50 (49.0)                        | 1 (3.5)                          | <0.001  |        |        |         |
| **MMF+T; +C; +E; +P; +C+P (%)** | 29, 16, 2, 1, 2 (28.4, 15.7, 2.0, 1.0, 2.0) | 1, 0, 0, 0, 0 (3.4, 0.0, 0.0, 0.0, 0.0) | <0.001  |        |        |         |
| **Double-triple IS excluding MMF** | 12 (11.8)                        | 2 (6.9)                          | 0.454   |        |        |         |
| **T+E, T+A, T+P, C+P, T+E+P (%)** | 3, 1, 5, 1, 2 (29.0, 10.0, 49.0, 10.0, 2.0) | 0, 0, 2, 0, 0 (0.0, 0.0, 6.9, 0.0, 0.0) | <0.001  |        |        |         |
| **Any double IS therapy**    | 58 (56.9)                        | 3 (10.3)                         | <0.001  |        |        |         |
| **Any triple IS therapy**    | 4 (3.9)                          | 0 (0.0)                          | 0.279   |        |        |         |
| **Serum IS levels or daily dose** |                                  |                                  |         |        |        |         |
| **Tacrolimus (ng/ml)**       | 4.26 ±0.46                       | 3.63 ±0.46                       | 0.678   |        |        |         |
| **Cyclosporine (ng/ml)**     | 12.4 ±2.52                       | 9.62 ±4.68                       | 0.467   |        |        |         |
| **Everolimus (ng/ml)**       | 0.45 ±0.16                       | 0.34 ±0.25                       | 0.523   |        |        |         |
| **MMF (g/day)**              | 0.93 ±0.09                       | 0.034 ±0.03                      | <0.001  |        |        |         |
| **Prednisone (mg/day)**       | 0.56 ±0.18                       | 0.34 ±0.27                       | 0.554   |        |        |         |
| **IS levels with respect to reference** |                                  |                                  |         |        |        |         |
| **Hemoglobin (g/dl)**        | 13.2 (12.1-14.8)                 | 14.0 (12.9-14.7)                 | 0.296   |        |        |         |
| **Leukocytes (n/µl)**        | 5,780 (4,500-6,610)              | 5,540 (4,680-6,330)              | 0.727   |        |        |         |
| **Neutrophils (n/µl)**       | 3,340 (2,770-4,180)              | 3,420 (2,700-4,100)              | 0.775   |        |        |         |
| **Albumin (g/dl)**           | 4.24 (4.03-4.53)                 | 4.23 (4.10-4.50)                 | 0.857   |        |        |         |
| **Bilirubin (mg/dl)**        | 0.59 (0.42-0.88)                 | 0.60 (0.43-1.01)                 | 0.351   |        |        |         |
| **eGFR (ml/min/1.73 m²)**    | 58.0 (45.3-70.6)                 | 72.9 (50.7-84.2)                 | 0.009   | 1.031  | 1.005-1.058 | 0.016 |
| **AST (U/ml)**               | 18 (14-23)                       | 21 (16-26)                       | 0.098   |        |        |         |
| **ALT (U/ml)**               | 15 (11-23)                       | 19 (14-21)                       | 0.041   |        |        |         |
| **INR**                      | 1.04 (0.98-1.10)                 | 1.10 (1.00-1.20)                 | 0.083   |        |        |         |
| **25-OH-Vitamin D (ng/ml)**  | 3.10 (2.56-3.50)                 | 32.0 (26.7-36.2)                 | 0.437   |        |        |         |

Logistic model estimation parameters: pseudo R² = 0.319; area under the ROC curve = 0.866; correct classification = 85.55%.

Association between prevaccination demographic and clinical characteristics of COVID-19-naïve liver transplanted patients (n = 131) with regards to the development of a positive (>−0.8 U/ml) or negative (<0.8 U/ml) anti-SARS-CoV-2 s-RBD antibody response, as assessed 3 weeks (19 days) after the first dose of the Pfizer BTN162b2 vaccine. Categorical parameters are presented as frequencies (%), and the Pearson chi-squared test was used for statistical comparisons. Continuous variables are presented as medians (IQR), and serum immunosuppressive drug levels are presented as the means (±SE). The rank-sum test (Mann-Whitney) was used for statistical comparisons. Stepwise regression with a forward approach was used to discriminate independent predictive variables to achieve a positive antibody response after vaccination in a multivariate logistic model analysis.

A, azathioprine; AH, alcoholic hepatitis; AI, autoimmune hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, cyclosporine; DM, diabetes mellitus; E, everolimus; eGFR, estimated glomerular filtration rate; HCC, hepatocellular carcinoma; HTN, arterial hypertension; INR, international normalized ratio; IS, immunosuppressive; LT, liver transplantation; NASH, non-alcoholic steatohepatitis; MMF, mycophenolate mofetil; P, prednisone; T, tacrolimus.

*reference blood levels evaluated within 1 month before vaccination for each IS drug were calculated in accordance with Cillo et al.35*
Table 3. Association of prevaccination demographic and clinical characteristics with antibody responses 6 months after the second dose of the Pfizer BTN162b2 vaccine.

| Univariate analysis | Multivariate analysis |
|---------------------|-----------------------|
|                      | Anti-s-RBD IgG negative (n = 26) | Anti-s-RBD IgG positive (n = 97) | p value | OR | 95% CI | p value |
| Age at LT (years)    | 60.5 (57.7-65.8)        | 57.4 (50.8-61.8) | 0.014 |
| Male sex             | 16 (61.5%)              | 72 (74.2%)       | 0.203 |
| BMI (kg/m²)          | 26.0 (23.5-228.7)       | 25.5 (23.4-28.5) | 0.923 |
| Months between LT and vaccination | 54.1 (18.9-98.4) | 118 (59.1-189) | 0.006 |
| Etiology: HEV, HBV, AH, AI, other (%) | 6, 6, 8, 3, 3 (23.1, 23.1, 30.8, 11.5, 11.5) | 20, 15, 46, 8, 8 (20.6, 15.5, 47.4, 8.2, 8.2) | 0.636 |
| HCC                  | 9 (34.6)                | 38 (39.2)        | 0.671 |
| DM                   | 8 (30.8)                | 34 (51.1)        | 0.683 |
| Dyslipidemia         | 7 (26.9)                | 20 (20.6)        | 0.490 |
| Alcohol consumption >40 g/day | 3 (11.5) | 7 (7.2) | 0.474 |
| HTN                  | 11 (42.3)               | 45 (46.4)        | 0.710 |
| Presence of esophageal varices | 2 (7.7) | 4 (4.1) | 0.453 |
| Presence of ascites  | 3 (11.5)                | 1 (1.0)          | 0.007 |
| p value              | 0.036                   | 0.003-0.486      | 0.012 |

| IS treatment         |                      |                  |     |
|----------------------|----------------------|------------------|
| Tacrolimus           | 18 (69.2)            | 63 (65.0)        | 0.683 |
| Cyclosporine         | 7 (26.9)             | 21 (21.7)        | 0.569 |
| MMF                  | 23 (88.5)            | 29 (29.9)        | <0.001 |
| Everolimus           | 1 (3.9)              | 11 (11.3)        | 0.253 |
| Prednisone           | 4 (15.4)             | 8 (8.3)          | 0.276 |
| Double-triple IS including MMF | 22 (84.6) | 24 (24.7) | <0.001 |
| MMF+T+; +C; +E; +P; +C+P (%) | 16, 4, 0, 1, 1 (61.5, 15.4, 0, 3.8, 3.8) | 11, 10, 2, 0, 1 (11.3, 10.3, 2.1, 0, 1) | 0.591 |
| Any double IS therapy | 22 (84.6) | 33 (34.0) | <0.001 |
| Any triple IS therapy | 2 (7.7) | 2 (2.1) | 0.151 |
| Serum IS drug levels or daily dose³ | Tacrolimus (ng/ml) | 4.02 ±0.59 | 4.35 ±0.82 | 0.276 |
| Cyclosporine (ng/ml) | 5.30 ±2.34           | 11.8 ±2.72       | 0.561 |
| MMF (g/day)          | 1.54 ±0.14           | 0.48 ±0.08       | <0.001 |
| Everolimus (ng/ml)   | 0.18 ±0.18           | 0.57 ±0.18       | 0.277 |
| Prednisone (mg/day)  | 0.67 ±0.36           | 0.46 ±0.17       | 0.303 |
| IS levels with respect to reference⁶ | Below | 13 (50.0) | 46 (47.4) | 0.815 |
|                      | Above                | 0 (0.0)          | 5 (5.2) | 0.237 |
| Hemoglobin (g/dl)    | 12.7 (11.6-13.6)     | 13.6 (12.8-15.0) | 0.007 |
| Leukocytes (n/µl)    | 4,550 (3,700-5,630)  | 5,980 (4,840-6,950) | 0.001 |
| Neutrophils (n/µl)   | 2,850 (1,890-3,780)  | 3,540 (2,910-4,310) | 0.016 |
| Albumin (g/dl)       | 4.50 (4.07-4.61)     | 4.24 (4.10-4.42) | 0.182 |
| Bilirubin (mg/dl)    | 0.57 (0.37-0.73)     | 0.63 (0.43-0.97) | 0.202 |
| eGFR (ml/min/1.73 m²) | 52.0 (45.3-70.6)    | 63.1 (48.4-80.1) | 0.072 |
| AST (IU/L)           | 15 (13-19)           | 20 (16-25)       | 0.001 |
| ALT (IU/L)           | 11.5 (9–17)          | 18 (12-27)       | 0.001 |
| INR                  | 1.04 (0.96-1.14)     | 1.04 (0.96-1.11) | 0.733 |
| 25-OH-Vitamin D (ng/ml) | 32.2 (28.6-35.0) | 31 (25.0-35.0) | 0.296 |

Logistic model estimation parameters: pseudo R² = 0.393; area under the ROC curve = 0.905; correct classification = 88.6%.
Association between prevaccination demographic and clinical characteristics of COVID-19 naïve liver transplanted patients (n = 123) with regards to the development of a positive (>−0.8 U/ml) or negative (<0.8 U/ml) anti-SARS-CoV-2 s-RBD antibody response, as assessed 6 months (165±4 days) after the second dose of the Pfizer® BTN162b2 vaccine. Categorical parameters are presented as frequencies (%), and the Pearson chi-squared test was used for statistical comparisons. Continuous variables are presented as medians (IQR), for serum immunosuppressive drug levels, they are presented as the means (±SE), and the rank-sum test (Mann-Whitney) was used for statistical comparisons.
Stepwise regression with a forward approach was used to discriminate independent predictive variables to achieve a positive antibody response after vaccination in a multivariate logistic model analysis.
A, azathioprine; AH, alcoholic hepatitis; AI, autoimmune hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, cyclosporine; DM, diabetes mellitus; E, everolimus; eGFR, estimated glomerular filtration rate; HCC, hepatocellular carcinoma; HTN, arterial hypertension; INR, international normalized ratio; IS, immunosuppressive; LT, liver transplantation; NASH, non-alcoholic steatohepatitis, MMF, mycophenolate mofetil; P, prednisone; T, tacrolimus.

³reference blood levels evaluated within 1 month before vaccination for each IS drug were calculated in accordance with Cillo et al. 2022

Journal of Hepatology 2022 vol. 77 152–162
Fig. 3. Anti-SARS-CoV-2 s-RBD antibody titers evaluated in COVID-19-naïve patients who did or did not receive mycophenolate mofetil. Antibody titers were measured 3 weeks (19 days) after the first dose of Pfizer-BioNTech® BNT162b2 vaccine, and after 1 month (31±2 days), 4 months (125±5 days), and 6 months (165±4 days) following the second vaccine dose with regards to the inclusion (light blue circles) or the exclusion (white circles) of mycophenolate mofetil monotherapy or in combination with other immunosuppressive drugs. Positive responders to vaccination were defined as those having reached an antibody titer ≥0.8 U/ml. Medians of antibody titers are reported for each time point, and the statistical analysis was performed by means of a non-parametric rank-sum (Mann-Whitney) test.

Fig. 4. Anti-SARS-CoV-2 s-RBD antibody titers in COVID-19-recovered and in COVID-19-naïve patients. Anti-SARS-CoV-2 s-RBD antibody titers in COVID-19-recovered (light blue circles) and in COVID-19-naïve (white circles) patients evaluated before and after 3 weeks (19 days) of the first dose of Pfizer-BioNTech® BNT162b2 vaccine, as well as after 1 month (31±2 days), 4 months (125±5 days), and 6 months (165±4 days) following the second vaccine dose. Positive responders to vaccination were defined as those having reached an antibody titer ≥0.8 U/ml. Medians of antibody titers are reported for each time point.
consumption at 4 months after the second vaccine dose (Table S5 and S6, respectively). A lower daily dose of MMF ($p=0.006$) in addition to a younger age at LT ($p=0.012$), alcohol consumption <40 g/day ($p<0.001$) and higher hemoglobin serum levels ($p=0.047$) were selected as independent predictors of a strong antibody response 6 months after vaccination (Table S7).

**Anti-SARS-CoV-2 s-RBD antibody response after BNT162b2 vaccination in LT COVID-19-recovered patients**

All 12 recovered COVID-19 patients presented a positive anti-SARS-CoV-2 s-RBD antibody response before vaccination. Furthermore, all increased their antibody titers following vaccination, which were significantly higher than those reported in COVID-19-naïve patients (Fig. 4). Interestingly, the median antibody titers developed 3 weeks after the first vaccine dose were significantly higher than those present before vaccination but not significantly different from those developed 1 month after the second vaccine dose. As reported for COVID-19 naïve patients, the mean antibody titers remained stable 4 and 6 months after vaccination, and none of the patients became antibody-negative. Unlike COVID-19-naïve patients, in COVID-19-recovered patients, the positive antibody response rate was the same in those receiving MMF ($n=6$) as in those who did not ($n=6$), and the median anti-SARS-CoV-2 s-RBD antibody titer was evaluated both at baseline and at each time point after vaccination (Fig. 5).

**Patients and controls reported side effects of anti-SARS-CoV-2 vaccination**

No severe side effects of vaccination were reported by either patients or controls. The more frequent reported side effect was modest pain in the vaccination injection site. This was reported in 23/58 (39.7%) controls and in 61/143 (42.6%) patients ($p=0.695$). Considering both vaccination doses, the frequency of systemic symptoms, such as fever, asthenia or myalgia, was reported in 12/58 (20.6%) controls and in 7/143 (4.9%) patients ($p<0.001$). During routine post-vaccination patient follow-up, no significant liver test abnormalities or clinical alterations were recorded.

**Discussion**

The long-term antibody response to the full course of BNT162b2 vaccination was recorded in 78.8% of COVID-naïve patients compared to 100% of the controls. Moreover, the peak of responder patients was reached 4 months after the second vaccine dose and remained stable up to 6 months. Recent reports indicated that the rate of antibody response to anti-SARS-CoV-2 vaccination in LT patients ranged from 45.5% to 82%, which is comparable to what we observed. However, all these studies evaluated the early (up to 3 months) immune response to vaccination. Our study presents, for the first time to our knowledge, data regarding the persistence of the antibody response to vaccination in the long term (up to 6 months). Our findings could be considered unexpected, since the effect of

![Fig. 5. Anti-SARS-CoV-2 s-RBD antibody titers evaluated in COVID-19-recovered patients who did or did not receive mycophenolate mofetil. Anti-SARS-CoV-2 s-RBD antibody titers evaluated in COVID-19-recovered (n = 12) patients before and after 3 weeks (19 days) of the first dose of Pfizer-BioNTech® BNT162b2 vaccine, as well as after 1 month (31±2 days), 4 months (125±5 days), and 6 months (165±4 days) following the second vaccine dose. Patients were divided with regard to adopting immunosuppressive treatment, including (light blue circles) or excluding (white circles) mycophenolate mofetil. Positive responders to vaccination were defined as those having reached an antibody titer >0.8 U/ml. Medians of antibody titers are reported for each time point, and the statistical analysis was performed by means of a non-parametric rank-sum (Mann-Whitney) test.](image-url)
immunosuppressive therapies could reduce antibody response duration over time more rapidly compared to immunocompetent patients. In a recent report conducted in healthcare professionals, 6 months after a full course of BNT162b2 vaccine, antibody titer decline was observed in approximately 89.6% of cases, and approximately 45% of them became seronegative.

However, the peak response in these patients was reached 1 month after the second vaccine dose, which was earlier than what we observed in our series. One possible explanation could be that the vaccine-induced antibody response in immunosuppressed patients might be delayed and therefore detected to last longer. Whether this kinetic antibody response might be used to plan the vaccine booster dose would require appropriate clinical studies. In any case, to maintain the immunological response to vaccination for a long time, and in the hope of increasing the number of patient responders, it is desirable that booster doses are carried out in this category of patients. This strategy appears to be further justified by the recent emergence of the Omicron viral variant, whose clinical impact on LT recipients is not yet known.

No sex differences in the rate of long-term vaccine antibody response were detected. This agrees with previous reports, but is in contrast to what was reported in LT recipients by Herrera et al., who documented a significantly lower response rate in females. However, this difference may be due to the different vaccine types (mRNA1273) adopted in these patients compared to BNT162b2 adopted in our patients.

A detrimental effect on the long-term antibody response to vaccination was exerted by increasing the daily dose of MMF rather than adopting double or triple immunosuppressive drug combinations. This confirms data reported both in liver and in other solid organ transplants. Rabinowich et al. showed that the use of MMF, in addition to a triple immunosuppression regimen, higher doses of steroids and lower eGFR were selected as negative predictors of vaccination response. In our series, only 13/131 (9.9%) patients were taking prednisone at a dosage >5 mg compared to 24/80 (30%) of those reported in the aforementioned study. Thus, the impact of steroids may be influenced by the different number of treated patients between the 2 studies. Furthermore, only 4 patients adopting triple immunosuppression were enrolled in our study. The influence of eGFR in conditioning the antibody vaccine response has seldom been evaluated in studies. In our series, a lower eGFR was selected as a negative predictor of vaccine response only 3 weeks after the first dose and not thereafter, which may be considered in agreement with what has been demonstrated in other series. In addition to the use of MMF, the presence of severe graft dysfunction leading to ascites formation and a lower serum leukocyte count were associated with a poor antibody response. Patients with advanced liver disease frequently show a suboptimal response to the anti-SARS-CoV-2 vaccine, which is also observable when employing other types of vaccines, such as that for hepatitis B. The detrimental combination of immunosuppressive treatment and the presence of graft cirrhosis after liver transplantation may justify our results. This may also explain the negative impact of a lower leukocyte count, which could be considered a surrogate marker of drug-induced immunosuppression and severe portal hypertension.

The strong vaccination response was evaluated adopting an antibody cut-off value of 100 U/ml. The percentage of responder patients 6 months after vaccination decreased from 78.8% if evaluated by an antibody cut-off of 0.8 U/ml to 29.3%. Interestingly, alcohol consumption >40 g/day had a negative impact on a strong vaccination response, in addition to previously reported negative predictors. This finding agrees with studies indicating that alcohol consumption decreases the humoral response to some vaccines, such as those against streptococcal pneumonia. Since alcohol relapse after LT is described in up to 5% of recipients, the effectiveness of anti-SARS-CoV-2 vaccination in this category of patients may be further reduced.

In COVID-19-recovered patients in our series, higher BMI, diabetes mellitus, and recurrent cirrhosis with portal hypertension were significantly more frequent than in COVID-19-naïve patients. In contrast, no significant differences were recorded regarding which immunosuppression treatment was adopted, particularly regarding the use of MMF. This may be expected, since the presence of metabolic comorbidities has been associated with a worse clinical outcome for COVID-19 in LT recipients but not as a factor leading to increased susceptibility to infection.

Similar consideration may be made with regard to the use of MMF, since it has been associated only with a more severe form of COVID-19, whereas the use of tacrolimus has been associated with a more benign course. Although in solid organ transplant recipients, a robust antibody and T cell response can be elicited regardless of COVID-19 severity, to our knowledge, no data are available on the impact of MMF use on developing natural immunity after SARS-CoV-2 infection in LT. The novelty of our findings, although derived from a small number of patients, is that among the COVID-19–recovered patients (50% treated with MMF), pre-vaccination anti-s-RBD protein antibody titers were detectable in all of them, independent of the use of MMF. Moreover, after the first vaccine dose, the antibody titer increased significantly and was comparable to that obtained 1 month after the second vaccine dose and remained positive up to 6 months, regardless of the use of MMF. This finding, if confirmed in a larger series, seems to support the observation that every immunosuppressive regimen adopted after LT has no meaningful impact on the ability to mount natural antibody responses after SARS-CoV-2 infection.

Regarding vaccine safety in our study, no severe adverse events were reported in either patients or controls, nor were any liver biochemical abnormalities found during routine post-vaccination patient follow-up. These observations agree with previous studies performed in solid organ transplant recipients.

Our study has some limitations. First, we did not evaluate the cellular immune response to vaccination. The correlation between humoral and cellular immune responses to anti-SARS-CoV-2 vaccination remains unclear. In a recent report evaluating 138 LT recipients, there was no evidence of a spike-specific T cell response in the majority of those without any detectable antibody response, suggesting that, in some cases, humoral and cellular immune responses could overlap. Second, we did not adopt systematic surveillance of patients to assess the efficacy of vaccination in preventing SARS-CoV-2 infection. Although this was not the aim of our study, we did not observe symptomatic SARS-CoV-2 infections in vaccinated patients during the follow-up period. Third, we enrolled patients with a long interval between transplant and vaccination; thus, our results may not be comparable to those obtainable when vaccination has been performed close to transplant.

In conclusion, in COVID-19-naïve LT patients, the anti-SARS-CoV-2 vaccination antibody response rate, although significantly
lower than that in controls, was maintained for at least 6 months. The increasing daily dose of MMF remains the main determinant of vaccination failure. This implies that modifying the daily dose of MMF in the immediate pre- and post-vaccination period may be hypothesized in COVID-19-naïve non-responders to increase the immunogenicity of booster vaccine doses. In contrast, LT recipients who recovered from COVID-19 had a full long-term antibody response to vaccination that was detectable after the first vaccine dose regardless of the use of MMF.

**Abbreviations**

LT, liver transplantation; MMF, mycophenolate mofetil; RBD, receptor-binding protein.

**Financial support**

The project did not receive financial support.

**Conflicts of interest**

The authors declare no conflicts of interest.

Please refer to the accompanying ICMJE disclosure forms for further details.

**Authors’ contributions**

PT, RP and LG had the idea for the study, and PT wrote the paper. LV collected the data and prepared the database. EFa and CF performed the statistical analysis and contributed to writing the paper. SC, AC, AS, and FC collected blood samples and performed all laboratory tests. DB, EFo, and EFu performed the clinical evaluation of the patients. RP and LR coordinated the vaccination processes and the logistics of blood sampling.

**Data availability statement**

De-identified data available on request.

**Acknowledgments**

The authors thank Cristina Minissale, Federica Sandri, Marcello Ferro, Deborah Di Giusto, Annalisa Sostero for their logistic support and all patients and their families for permitting the realization of the study.

**Supplementary data**

Supplementary data to this article can be found online at [https://doi.org/10.1016/j.jhep.2022.02.015](https://doi.org/10.1016/j.jhep.2022.02.015).

**References**

[1] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–273.

[2] Trapani S, Masiero L, Puoti F, Rota MC, Del Manso M, Lombardini L, et al. Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: a nationwide population-based study. Am J Transplant 2021;21:2509–2521.

[3] Becchetti C, Ghosh SG, Dufour JF, Banz V. COVID-19 in liver transplant recipients: a systematic review. J Clin Med 2021;10(17):4015.

[4] Becchetti C, Zambelli MF, Fasulo L, Donato MF, Invernizzi F, Detty O, et al. COVID-19 in an international European liver transplant cohort. Gut 2020;69:1832–1840.

[5] Belli LS, Duvoux C, Cortesi PA, Facchetti R, Iacopo S, Perricone G, et al. COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study. Gut 2021;70:1914–1924.

[6] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–2615.

[7] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–416.

[8] Kageyama T, Ikeda K, Tanaka S, Taniguchi T, Igarì H, Onouchi Y, et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin Microbiol Infect 2021;27(12):1861.e1–1861.e5.

[9] Khoury DS, Cromer D, Reynolds A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205–1211.

[10] Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segel DL, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:2204–2206.

[11] Strauss AT, Hallett AM, Boyarsky BJ, Ou MT, Boyarsky AM, Werbel WA, Avery RK, et al. Antibody response to severe acute respiratory syndrome-coronavirus-2 messenger RNA vaccines in liver transplant recipients. Liver Transpl 2021;27(12):1852–1856.

[12] Thuluvath PJ, Roberts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol 2021;75(6):1434–1438.

[13] Comberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol 2021;74:945–951.

[14] Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goeacher EK, et al. AASLD expert panel consensus statement: vaccines to prevent COVID-19 infection in patients with liver disease. Hepatology 2021;74(2):1049–1064.

[15] Russo FP, Piano S, Bruno R, Burra P, Puoti M, Masarone M, et al. Italian association for the study of the liver position statement on SARS-CoV2 vaccination. Dig Liver Dis 2021;53:677–681.

[16] Tonitto P, Aghemo A, Grossi P, Burra P. Permanent Transplant Commission of the Italian Association for the Study of the L. Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation in and liver transplant recipients. Dig Liver Dis 2021;53(10):1232–1234.

[17] McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590:630–634.

[18] Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol 2021;75(2):435–438.

[19] Herrera S, Colmenero J, Pascal M, Escobedo M, Castel MA, Sole-Gonzalez E, et al. Humoral and cellular immune response and safety of mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. Am J Transplant 2021;21(12):3971–3979.

[20] Guarino M, Cossiga V, Esposito I, Alessandro F, Morisco F. Effectiveness of SARS-CoV-2 vaccination in liver transplant patients: the debate is open! J Hepatol 2021;76(1):237–239.

[21] Adhikari-Alavieh J, Frey F, Passenberg M, Korth J, Zmudzinski J, Anastasiou OE, et al. Humoral response to SARS-CoV-2 vaccination in liver transplant recipients–A single-center experience. Vaccines (Basel) 2021;9(7):738.

[22] Rueter DF, Schaub GM, Duengelhof PM, Haag F, Brehm TH, Fathi A, et al. SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol 2021;20(1):162–172.

[23] Bayart JL, Douxfils J, Gillot C, David C, Mullier F, Elsen M, et al. Waning of IgG, total and neutralizing antibodies 6 Months post-vaccination with BNT162b2 in healthcare workers. Vaccines (Basel) 2021;9(10):1092.

[24] Hall VG, Ferreira VH, Ierullo M, Ku T, Marinelli T, Majchrzak-Kita B, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients-A single-center experience. Vaccines (Basel) 2021;10(12):3980–3989.

[25] Rodriguez-Tajes S, Pocurull A, Lens S, Marino Z, Olivas I, Soy G, et al. Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis. J Viral Hepat 2021;28:1019–1024.

[26] Yongxiang W, Zongfang L, Guowei L, Zongzheng J, Xi C, Tao W. Effects of splenomegaly and splenic macrophage activity in hypersplenism due to liver cirrhosis. J Hepatol 2021;75(2):435–441.

[27] Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev 2019;32(2):e00084–18.

[28] Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA 2021;326:165–176.
Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr 2020;14:535–545.

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110–118.

Colmenero J, Rodriguez-Peralvarez M, Salcedo M, Arias-Milla A, Munoz-Serrano A, Graus J, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol 2021;74:148–155.

Belli LS, Fondevila C, Cortesi PA, Conti S, Karam V, Adam R, et al. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study. Gastroenterology 2021;160(4):1151–1163.

Hartzell S, Bin S, Benedetti C, Haverly M, Gallon L, Zaza G, et al. Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. Am J Transpl 2020;20:3149–3161.

Fernandez-Ruiz M, Olea B, Almendro-Vazquez P, Gimenez E, Marcauzco A, San Juan R, et al. T cell-mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19. Am J Transpl 2021;21:2785–2794.

Cillo U, De Carlis L, Del Gaudio M, De Simone P, Fagiuoli S, Lupo F, et al. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int 2020;14:930–943.